Abiopharma

🔍 Goldberg Andrew D. (Director)

Company: Tarsus Pharmaceuticals, Inc. (TARS)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 3,837 shares of Stock Option (right to buy) at $64.34 per share (Derivative)
  Date: 2026-06-25 | Code: A | Expires: 2036-06-24 | equity_swap_involved: 0 | shares_owned_after: 3,837.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,417 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,417.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
• F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
• F3: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.